bioRxiv Science⌕ Search

Biology subjects

Martin, H. L.

Publications and source records attributed to Martin, H. L..

2 recordsLinked to original sources

ΔCt-Informed, Calibrated Logistic Regression Accurately Attributes mecA in Staphylococcus aureus-Positive Wound Specimens.

In wound specimens, co-detection of mecA and Staphylococcus aureus by PCR does not necessarily indicate MRSA because coagulase-negative staphylococci (CoNS) frequently harbor mecA. We evaluated a {Delta}Ct-informed, biologically gated, calibrated logistic regression to attribute mecA to S. aureus versus CoNS. Using paired culture/AST and multiplex real-time PCR Ct values (internal n=93; external n=47), we trained 5-fold cross-validated models in the culture-positive S. aureus subset (n=36) and applied an S. aureus PCR gate (no attribution when S. aureus PCR is negative). The primary model achieved sensitivity 90.9% and specificity 92.0% for MRSA attribution with AUC 0.931 (out-of-fold). Decision curve analysis showed positive net benefit across clinically relevant thresholds; at the prespecified 50% cutoff, the model achieved a net benefit of 0.222 compared with negative benefit for a treat-all strategy. In an external cohort, S. aureus detection by PCR versus culture showed 92.3% sensitivity and 97.1% specificity; within S. aureus PCR-positives (n=12), MRSA attribution reached 100% sensitivity and 87.5% specificity (accuracy = 91.7%). This framework improves mecA interpretability in polymicrobial specimens and can reduce unnecessary MRSA-directed antibiotics.

microbiology↗

RAS-inhibiting biologics identify and probe druggable pockets including an SII-α3 allosteric site.

RAS mutations are the most common oncogenic drivers across human cancers, but there remains a paucity of clinically-validated pharmacological inhibitors of RAS, as druggable pockets have proven difficult to identify. We have identified two RAS-binding Affimer proteins, K3 and K6, that inhibit nucleotide exchange and downstream signalling pathways with distinct isoform and mutant profiles. Affimer K6 is the first biologic to bind in the SI/SII pocket, whilst Affimer K3 is the first non-covalent inhibitor of the SII region, revealing a novel RAS conformer with a large, druggable SII/3 pocket. This work demonstrates the potential of using biologics with small interface surfaces to select novel druggable conformations in conjunction with pharmacophore identification for hard-to-drug proteins.

molecular biology↗